JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Froidevaux, S.
Right arrow Articles by Eberle, A. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Froidevaux, S.
Right arrow Articles by Eberle, A. N.

A Novel DOTA-{alpha}-Melanocyte–Stimulating Hormone Analog for Metastatic Melanoma Diagnosis

Sylvie Froidevaux, PhD, Martine Calame-Christe, PhD, Heidi Tanner, Lazar Sumanovski, BSc and Alex N. Eberle, PhD

Laboratory of Endocrinology, Department of Research, University Hospital and University Children’s Hospital, Basel, Switzerland



View larger version (19K):

[in a new window]
 
FIGURE 1. Structure of MSHoct, NDP-MSH, {alpha}-MSH, and DOTA-{alpha}-MSH analog.

 


View larger version (38K):

[in a new window]
 
FIGURE 2. Tumor-to-organ uptake ratios 4 h after injection. 111In-DOTA-MSHoct (white bars) or 111In-DOTA-NDP-MSH (black bars) was injected into melanoma-bearing mice, and tissues were collected 4 h after injection. Results are expressed as tumor-to-tissue uptake ratios (mean ± SEM, n = 4–8). *P < 0.05 vs. 111In-DOTA-NDP-MSH. {dagger}P < 0.01 vs. 111In-DOTA-NDP-MSH. {ddagger}P < 0.001 vs. 111In-DOTA-NDP-MSH. §P < 0.0001 vs. 111In-DOTA-NDP-MSH.

 


View larger version (61K):

[in a new window]
 
FIGURE 3. Autoradiographs of tissue sections from nonmalignant organs and primary melanoma: melanoma with surrounding skin tissue (A), liver (B), and transverse section of kidney (C). 111In-DOTA-MSHoct was injected into melanoma-bearing mice, and tissues of interest were collected 4 h after injection and immediately fixed. After sectioning, tissues were exposed to storage phosphor plate. Similar autoradiographs were obtained for 3 mice.

 


View larger version (67K):

[in a new window]
 
FIGURE 4. Autoradiographs of tissue sections from lung and liver colonized by melanoma metastases: lung with melanotic melanoma metastases (A), lung with amelanotic melanoma metastases (B), liver with melanotic melanoma metastases (C). 111In-DOTA-MSHoct was injected into mice inoculated with B16F1 cells, and tissues showing macroscopic metastases were collected 4 h after injection and immediately fixed. After sectioning, tissues were exposed to storage phosphor plate (left) and later to scanner (right). Arrows indicate amelanotic/melanotic metastatic nodules.

 


View larger version (15K):

[in a new window]
 
FIGURE 5. Radio-RP-HPLC analysis of urine samples 4 or 24 h after injection of 111In-DOTA-MSHoct. Urine samples were collected from melanoma-bearing mice (n = 4) and were analyzed by RP-HPLC after protein precipitation. Elution time of intact 111In-DOTA-MSHoct was 15.9 min.

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.